US Patent

US9925150 — Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine

Formulation · Assigned to UCB Pharma GmbH · Expires 2032-03-01 · 6y remaining

Vulnerability score 48/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a method for stabilizing rotigotine using a solid dispersion of polyvinylpyrrolidone and rotigotine in a specific weight ratio.

USPTO Abstract

The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.

Drugs covered by this patent

Patent Metadata

Patent number
US9925150
Jurisdiction
US
Classification
Formulation
Expires
2032-03-01
Drug substance claim
No
Drug product claim
Yes
Assignee
UCB Pharma GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.